AbbVie Inc. vs Johnson & Johnson — Stock Comparison
AbbVie Inc. (ABBV) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson scores ahead of AbbVie Inc. on Q·Score (7.1 vs 6.1 out of 10), led by Quality (9.3 vs 5.2) and Health (6.5 vs 5.5). AbbVie Inc. scores higher on Sentiment, reflecting stronger analyst and market sentiment. Analyst consensus targets imply greater upside for ABBV (+25.1%) than for JNJ (+14.1%).
Q·Score Breakdown
75% of 32 covering analysts have a positive rating.
⚠ earnings contracting 46% year-over-year.
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ABBV vs JNJ: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus AbbVie Inc. (ABBV) at 6.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ABBV or JNJ?
AbbVie Inc. (ABBV) scores higher on Growth (5.1/10 vs 5.1/10). AbbVie Inc. reports revenue growth (12.4% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ABBV or JNJ more attractively valued?
AbbVie Inc. (ABBV) scores higher on Valuation (7.7/10 vs 7.3/10). ABBV trades at 12.4× P/E versus JNJ at 17.4×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ABBV vs JNJ?
There are 30 analysts covering ABBV with a consensus price target of $252.23, and 24 analysts covering JNJ with a consensus target of $252.42. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ABBV or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 5.2/10). Net profit margin: ABBV at 5.8%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ABBV or JNJ?
Johnson & Johnson (JNJ) scores higher on Financial Health (6.5/10 vs 5.5/10). Market beta: ABBV at 0.30, JNJ at 0.26. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ABBV and JNJ?
AbbVie Inc. (ABBV) has a market capitalisation of $356.5B, while Johnson & Johnson (JNJ) has a market cap of $532.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do ABBV or JNJ pay dividends?
ABBV pays a dividend yield of 3.43%, while JNJ pays a dividend yield of 2.42%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →